Clinical Trials Logo

HER-2 Positive Breast Cancer clinical trials

View clinical trials related to HER-2 Positive Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06100874 Recruiting - Clinical trials for Breast Cancer Female

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: - Sacituzumab govitecan (a type of antibody-drug conjugate) - Trastuzumab (Herceptin) (a type of monoclonal antibody) - Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) - Trastuzumab biosimilar drug

NCT ID: NCT05871918 Recruiting - Clinical trials for HER-2 Positive Breast Cancer

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Start date: October 8, 2022
Phase: Phase 3
Study type: Interventional

The study is being conducted to assess the efficacy and safety of anthracycline-containing ddEC-THP intensive regimen and an anthracycline-free TCbHP neoadjuvant therapy for HER2-positive breast cancer